Federal health advisers voted overwhelmingly against an experimental treatment for Lou Gehrig's disease at a Wednesday meeting.
FILE - A U.S. Food and Drug Administration building is seen behind FDA logos at a bus stop on the agency's campus in Silver Spring, Md., on Aug. 2, 2018.
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
FDA to Review Experimental ALS Treatment This WeekThe Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig's disease, the culmination of a yearslong lobbying effort by patients with the fatal neurodegenerative disease. Those advocates still face one giant hurdle: FDA...
Les mer »
| FDA advisers weigh divisive ALS drug todayThere's a heated debate over the investigational treatment called NurOwn.
Les mer »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
Les mer »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
Les mer »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
Les mer »
FDA advisers vote against experimental ALS treatment pushed by patientsFederal health advisers have voted overwhelmingly against recommending approval of an experimental treatment for Lou Gehrig's disease, the fatal muscle-wasting disease.
Les mer »